ReviewInternational journal of nanomedicine2026
Nanoparticle-Mediated Brain-Targeted Drug Delivery for Methamphetamine Use Disorder: Advances, Challenges and Translational Perspectives.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methamphetamine use disorder (MUD) poses a significant global health challenge, lacking FDA-approved pharmacotherapies. Despite extensive exploration of therapeutic targets and interventions, effective treatment remains scarce due to challenges in delivering therapeutic agents to relevant brain regions at effective concentrations. Nanoparticle-mediated delivery offers a promising approach for transporting various therapeutic cargos to the central nervous system, including small molecules, nucleic acids, peptides, proteins, and gene-editing systems. However, the application of nanomedicine strategies in addressing the unique pathophysiological characteristics of MUD has not been systematically assessed. This review presents a problem-focused analysis of how lipid-based, polymeric, inorganic, biological, and hybrid nanocarriers tackle successive delivery obstacles such as systemic stability, blood-brain barrier (BBB) penetration, brain region-specific distribution, and controlled release of intracellular cargo. We compare preclinical nanotherapeutic approaches encompassing small-molecule neuroprotective agents, anti-METH vaccines, gene-silencing RNAs, neurotrophic proteins, and emerging gene-editing methods, outlining their respective benefits, limitations, and design considerations. Additionally, we explore key factors influencing nanomedicine performance in MUD, including protein corona formation, the impact of METH-related BBB dysfunction and neuroinflammation on nanoparticle distribution, and the disparity between acute animal models and chronic human MUD with relapse tendencies. In conclusion, we present a systematic framework for aligning nanocarrier characteristics with distinct delivery obstacles and therapeutic needs. We also emphasize forthcoming avenues such as disease-triggered nanocarriers, targeted delivery to specific regions, combined nanomedical approaches, theranostic strategies, and standardized assessments of biodistribution, effectiveness, safety, and translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.